Bruce E. Johnson, MD, of Dana-Farber Cancer Institute, offers his expert perspective on single-arm drug approvals for targeted agents between 2016 and 2020, the need for biomarker testing, and the societal costs of drug development (Abstract PL04.03).
Luis M. Montuenga, PhD, of the University of Navarra, discusses the potential contributions of biomarkers, promising biomarker panels being tested and published, the need to standardize biospecimen collection, and how to improve the sensitivity of these biomarkers (Abstract PL05.06).
Hossein Borghaei, DO, of Fox Chase Cancer Center, discusses phase I results from a study of AMG 757, an experimental bispecific T-cell–engager (BiTE) immune therapy aimed at the DLL3 molecular target in patients with small cell lung cancer. At this early stage, results show clinical efficacy and safety, with 37% of 51 evaluable patients exhibiting disease control (Abstract OA11.03).
Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, invites his colleagues to enroll their patients in a large prospective study, for which he serves as Principal Investigator. The study is searching for solutions for treating patients with lung cancer who also have the coronavirus, because so many experience an aggressive course of infection.
Jill Feldman, a patient advocate and lung cancer survivor, discusses the current challenges and potential solutions to including more people of color and those in underserved communities in clinical trial research (Abstract PL04.06).
Roy S. Herbst, MD, PhD, of Yale University, discusses results from the LUNG-MAP Master Protocol, which support the planned use of circulating tumor DNA for enrollment onto LUNG-MAP substudies, with a positive finding meriting inclusion in study; a negative finding, while considered inconclusive, requires the use of tissue samples (Abstract MA08.10).
